Vepsitamab (AMG 199) is a bispecific T-cell engager (HLE BiTE) that binds to MUC17 and CD3. Vepsitamab directs CD3-positive cells to target MUC17-positive cells. Vepsitamab induces cell activation and proliferation. Vepsitamab is applicable to research related to gastric cancer and gastroesophageal junction (g/gej) cancer[1].
Molecular Weight:
(105 kDa)
Purity:
98.44
CAS Number:
[2413453-53-7]
Target:
CD3
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted